ALA today announced a CR for its iNKT trial which still waits for its IND to be allowed to commence.
Anyway, huge discount and oppies similar to what Hopper has done here at CHM. That came on the back of a failed cap raising in January that was too good to be true. So many similarities.
What does it mean CHM?
1. Maybe it is really hard to get funding and Hopper is actually trying and achieving the best possible?
2. And that is the most important point: ALA was way too overvalued for not even having an IND and that should put the focus back on CHM which got their trials running and have produced Complete Responses with their CD19 CAR-T NK-cell platforms.
CHM is still on top of ASX listed companies doing clinical trials in the CAR-T space and the least valued too.
Maybe ALA money will find its way into a real CAR-T company, not just a wannabe ( at this stage ).
ALA today announced a CR for its iNKT trial which still waits...
Add to My Watchlist
What is My Watchlist?
